Emerging evidence suggests that retatrutide, a novel dual-action peptide compound targeting both GLP-1 and GIP receptors, may represent a significant advance in obesity treatment therapies. Unlike current https://reta566112.activoblog.com/1293192/retatrutide-the-emerging-peptide-for-weight-management